Drug Trial Radar · NCT02786537
Study of Oral Treatments for Hepatitis C
Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,275
Actual
Start
Jun 2016
Primary completion
Jun 13, 2019
Study completion Sep 2, 2020
Sponsor
- Lead sponsor
- University of FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie
- First posted
- Jun 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.
Conditions
- Chronic Hepatitis C
Interventions
SOF/LDV (sofosbuvir/ledipasvir)Drug
Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)Drug
Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
EBR/GZR (elbasvir/grazoprevir)Drug
Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
RibavirinDrug
200 mg pills (1-3 pills, 1-2 times per day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Virologic Response (SVR12) mITT With Imputation-Phase 1 and 2 EBR/GZR, SOF/LDVTime frame: 12 weeks post-treatment
- Phase 1/2 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)Time frame: 12-24 weeks post HCV treatment
- Phase 1-Sustained Virologic Response (SVR12) mITT With ImputationTime frame: 12 weeks post-treatment
- Phase 1 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)Time frame: 12 -24 weeks post-treatment
- Mean Change in Headache-PRO Scores -Phase 1Time frame: Baseline to On-Treatment
- Mean Change in Headache-EBR/GZR and SOF/LDVTime frame: Baseline to On-Treatment
- Median Change in Headache -Phase 1Time frame: 12 weeks (Baseline and Average On-treatment Score)
- Median Change in Headache-Phase 2Time frame: Baseline -on Treatment (12-16 weeks)
- Mean Change in Nausea/Vomiting PRO Score -Phase 1Time frame: Baseline to On-Treatment
- Mean Change in Nausea/Vomiting PROMIS Score -EBR/GZR vs. LDV/SOFTime frame: Baseline and Average On-Treatment Score
- Median Change in Nausea PRO Score -Phase 1Time frame: Baseline to end of treatment
- Median Change in Nausea PROMIS Score-EBR/GZR SOF/LDVTime frame: Baseline- On Treatment (up to 16 weeks)
- Mean Change in Fatigue PRO Score -Phase 1Time frame: Baseline to On-treatment
- Mean Change in Fatigue PRO -EBR/GZR vs SOF/LDVTime frame: Baseline and Average On-Treatment Score
- Median Change in Fatigue -Phase 1Time frame: Baseline to End of Treatment
- Median Change in Fatigue-Phase 2Time frame: Baseline-On Treatment (up to 16 weeks)
- Mean Change in HCV- PRO- Phase 1Time frame: Baseline to End of Treatment
- Median Change in HCV-PRO (Overall Well Being) -Phase 1Time frame: Baseline to End of Treatment
- Mean Change in HCV-PRO (Functional Well-being) EBR/GZR vs. SOF/LDV Score-Phase 2Time frame: End of Treatment - Baseline
- 16 Wk EBR/GZR With RBV Efficacy on Patients With HCV RASsTime frame: 12 weeks post treatment
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Liver Wellness Center
Little Rock, Arkansas
Stanford University
Palo Alto, California
UCSD Medical Center
San Diego, California
UCSF/Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California
Univ of California, San Francisco
San Francisco, California
Yale University Digestive Diseases
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
Howard University
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
University of Florida, Jacksonville
Jacksonville, Florida
University of Miami/Schiff Center for Liver Diseases
Miami, Florida
Orlando Immunology Center
Orlando, Florida
Internal Medicine Associates of Wellstar Atlanta Medical Center
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Northwestern University
Chicago, Illinois
Indiana University Medical Center
Indianapolis, Indiana
John Hopkins University
Lutherville, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
GI Associates & Endoscopy Center
Flowood, Mississippi
Saint Louis University
St Louis, Missouri
University of Nebraska Medical Ctr
Omaha, Nebraska
Southwest CARE Center
Santa Fe, New Mexico
Mt. Sinai Beth Israel
New York, New York
New York Langone Medical Center
New York, New York
Weill Cornell Medical College
New York, New York
Columbia University Medical Center
New York, New York
Mountain View Medical Center
Valatie, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Research Specialist of Texas
Houston, Texas
Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia)
Richmond, Virginia
Virginia Commonwealth University
Richmond, Virginia
Virginia Mason Medical Center
Seattle, Washington
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.